These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 16597537

  • 1. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
    Paredes I, Ahmed M, Foster CS.
    Ocul Immunol Inflamm; 2006 Apr; 14(2):87-90. PubMed ID: 16597537
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA.
    Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
    [Abstract] [Full Text] [Related]

  • 3. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.
    Lai TY, Chan RP, Chan CK, Lam DS.
    Eye (Lond); 2009 Mar; 23(3):543-8. PubMed ID: 18369377
    [Abstract] [Full Text] [Related]

  • 4. Vogt-Koyanagi-Harada disease in Thai patients.
    Tesavibul N, Sansanayuth W.
    J Med Assoc Thai; 2005 Nov; 88 Suppl 9():S26-30. PubMed ID: 16681048
    [Abstract] [Full Text] [Related]

  • 5. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.
    Urzua CA, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A, Vásquez DH, Gatica H, Guerrero J.
    Acta Ophthalmol; 2015 Sep; 93(6):e475-80. PubMed ID: 25565265
    [Abstract] [Full Text] [Related]

  • 6. Vogt-Koyanagi-Harada disease: clinical outcomes.
    Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA.
    Am J Ophthalmol; 2005 Oct; 140(4):674-8. PubMed ID: 16226518
    [Abstract] [Full Text] [Related]

  • 7. [Vogt-Koyanagi-Harada syndrome: glucocorticoid therapy and visual prognosis].
    Zhang M, Liu Q, Min H, Du H, Hu T.
    Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):200-3. PubMed ID: 12133385
    [Abstract] [Full Text] [Related]

  • 8. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
    Agarwal M, Ganesh SK, Biswas J.
    Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
    [Abstract] [Full Text] [Related]

  • 9. Choroidal folds in acute Vogt-Koyanagi-Harada disease.
    Zhao C, Zhang M, Wen X, Dong F, Han B, Du H.
    Ocul Immunol Inflamm; 2009 Dec; 17(4):282-8. PubMed ID: 19657984
    [Abstract] [Full Text] [Related]

  • 10. Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.
    Berker N, Ozdamar Y, Soykan E, Ozdal P, Ozkan SS.
    Ocul Immunol Inflamm; 2007 Dec; 15(4):351-7. PubMed ID: 17763135
    [Abstract] [Full Text] [Related]

  • 11. [Therapeutic regimen in Vogt-Koyanagi-Harada syndrome].
    Yang P, Wang H, Zhou H, Zhong H, Li F, Huang X, Zhong H, Fu T.
    Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):196-9. PubMed ID: 12133384
    [Abstract] [Full Text] [Related]

  • 12. The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease.
    Chee SP, Jap A.
    Br J Ophthalmol; 2013 Feb; 97(2):130-3. PubMed ID: 23212203
    [Abstract] [Full Text] [Related]

  • 13. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM.
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.
    Cuchacovich M, Solanes F, Díaz G, Cermenati T, Avila S, Verdaguer J, Verdaguer JI, Carpentier C, Stopel J, Rojas B, Traipe L, Gallardo P, Sabugo F, Zanoli M, Merino G, Villarroel F.
    Ocul Immunol Inflamm; 2010 Jun; 18(3):200-7. PubMed ID: 20482399
    [Abstract] [Full Text] [Related]

  • 15. Management of pediatric Vogt-Koyanagi- Harada (VKH)-associated panuveitis.
    Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA.
    Ocul Immunol Inflamm; 2006 Apr; 14(2):91-8. PubMed ID: 16597538
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
    Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D.
    Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease.
    Fang W, Zhou H, Yang P, Huang X, Wang L, Kijlstra A.
    Br J Ophthalmol; 2008 Feb; 92(2):182-5. PubMed ID: 17965105
    [Abstract] [Full Text] [Related]

  • 18. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.
    Wang Y, Gaudio PA.
    Ocul Immunol Inflamm; 2008 Feb; 16(4):167-71. PubMed ID: 18716952
    [Abstract] [Full Text] [Related]

  • 19. Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.
    Martin TD, Rathinam SR, Cunningham ET.
    Retina; 2010 Feb; 30(7):1113-21. PubMed ID: 20168275
    [Abstract] [Full Text] [Related]

  • 20. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
    Concha-Del Río LE, Gómez L, Arellanes-García L.
    Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.